<DOC>
	<DOCNO>NCT01096472</DOCNO>
	<brief_summary>The aim study determine efficacy safety topical application combinational cream LAS41003 compare application mono-substances daily treatment patient inflammatory tinea pedis .</brief_summary>
	<brief_title>Efficacy Safety LAS41003 Treatment Inflammatory Tinea Pedis</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<criteria>presence tinea pedis cause dermatophytes one foot , characterize physician 's global assessment score 2 ( `` notable sign symptom exist '' ) 3 ( `` prominent sign symptom exist '' ) baseline ; physical examination must without disease finding unless investigator considers abnormality irrelevant outcome study ; female volunteer childbearing potential must either surgically sterile ( hysterectomy tubal ligation ) agree use reliable method contraception failure rate le 1 % per year use consistently correctly implant , injectables , combine oral contraceptive , intra uterine device [ IUDs ] , sexual abstinence vasectomize partner ; patient must willing able comply requirement trial protocol ; write informed consent obtain . patient hyperkeratotic chronic plantar tinea pedis ( moccasin type ) ; receive systemic therapy cytotoxic immunosuppressive drug either concurrently within 12 week baseline visit ; oral antifungal therapy within three month study entry ( 8 month oral terbinafine ) , systemic antibiotic corticosteroid treatment , topical corticosteroid within 30 day study entry ; patient diabetes ; patient compromised circulation ; evidence drug alcohol abuse ; pregnancy nursing ; symptom clinically significant illness may influence outcome study four week treatment phase study ; participation treatment phase another clinical study within last four week prior first administration investigational drug study ; know allergic reaction component study preparation , hypersensitivity cetylstearyl alcohol ; treatment systemic locally act medication might counter influence study aim within two week treatment phase study ( e.g . glucocorticosteroids ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Tinea pedis</keyword>
</DOC>